# A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

> **NCT00566202** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 67 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Placebo
- **DRUG:** Escitalopram
- **DRUG:** JNJ-18038683

## Key facts

- **NCT ID:** NCT00566202
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00566202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00566202, "A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00566202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*